Veru/$VERU
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Veru
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Ticker
$VERU
Sector
Primary listing
Employees
20
Headquarters
Website
Veru Metrics
BasicAdvanced
$37M
-
-$1.55
-1.00
-
Price and volume
Market cap
$37M
Beta
-1
52-week high
$4.59
52-week low
$2.10
Average daily volume
165K
Financial strength
Current ratio
2.43
Quick ratio
0.324
Long term debt to equity
12.862
Total debt to equity
17.002
Profitability
EBITDA (TTM)
-35.379
Management effectiveness
Return on assets (TTM)
-49.21%
Return on equity (TTM)
-61.92%
Valuation
Price to book
1.86
Price to tangible book (TTM)
2.98
Price to free cash flow (TTM)
-1.136
Free cash flow yield (TTM)
-88.04%
Free cash flow per share (TTM)
-2.051
Growth
Earnings per share change (TTM)
-44.64%
3-year earnings per share growth (CAGR)
-47.11%
10-year earnings per share growth (CAGR)
0.34%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $37M as of January 07, 2026.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of January 07, 2026.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of January 07, 2026.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -1. This means that it has an inverse relation to market volatility.